Faivre Emily J, Daniel Andrea R, Hillard Christopher J, Lange Carol A
Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA.
Mol Endocrinol. 2008 Apr;22(4):823-37. doi: 10.1210/me.2007-0437. Epub 2008 Jan 17.
Human progesterone receptors (PR) rapidly activate cytosolic signaling pathways, in addition to their classical function as ligand-activated transcription factors. Using ER+/PR-B+ T47D breast cancer cells, we probed the role of progestin-stimulated rapid PR signaling in the transcriptional regulation of target genes involved in breast cancer cell proliferation. Epidermal growth factor receptor (EGFR) was rapidly activated after a 10-min treatment with R5020. Progestin induced EGFR-, c-Src-, and MAPK-dependent phosphorylation of PR-B on the MAPK consensus site, Ser345. Ser345-phosphorylated PR-B receptors strongly associated with specificity protein 1 (Sp1) transcription factors to regulate PR cell cycle (p21) and growth-promoting (EGFR) target genes whose promoters lack canonical progesterone response element sequences. Inhibitors of EGFR, c-Src, or MAPK activities blocked PR tethering to Sp1 and progestin-stimulated S-phase entry. Mutant PR-B receptors defective for c-Src binding (mPro) were not phosphorylated on Ser345 in response to progestin and failed to interact with Sp1. Hormone-induced complexes containing Sp1 and wild-type PR-B, but not S345A or mPro PR-B, were recruited to Sp1 sites within the endogenous p21 promoter. Progestin-induced S-phase entry was attenuated in T47D cells containing wild-type PR-B and treated with EGFR, c-Src, or MAPK kinase inhibitors or in T47D cells stably expressing mPro or mutant DNA-binding domain PR-B. In sum, rapid progestin-activated PR signaling leads to PR Ser345 phosphorylation and tethering to Sp1. These events are critical for progestin-stimulated regulation of Sp1 target genes and breast cancer cell proliferation. Our data demonstrate the therapeutic potential for PR-targeted breast cancer treatment by exploiting multiple nodes along the PR signaling pathway, including PR-B, EGFR, c-Src, MAPK, or Sp1.
人类孕酮受体(PR)除了作为配体激活的转录因子具有经典功能外,还能快速激活细胞溶质信号通路。我们使用雌激素受体阳性/孕酮受体B亚型阳性(ER+/PR-B+)的T47D乳腺癌细胞,探究了孕激素刺激的PR快速信号传导在参与乳腺癌细胞增殖的靶基因转录调控中的作用。用R5020处理10分钟后,表皮生长因子受体(EGFR)被快速激活。孕激素诱导PR-B在丝裂原活化蛋白激酶(MAPK)的共有位点Ser345发生EGFR、c-Src和MAPK依赖性磷酸化。Ser345磷酸化的PR-B受体与特异性蛋白1(Sp1)转录因子强烈结合,以调控PR细胞周期(p21)和生长促进(EGFR)靶基因,这些靶基因的启动子缺乏典型的孕酮反应元件序列。EGFR、c-Src或MAPK活性抑制剂可阻断PR与Sp1的结合以及孕激素刺激的S期进入。对c-Src结合有缺陷的突变PR-B受体(mPro)在孕激素作用下Ser345未发生磷酸化,且无法与Sp1相互作用。激素诱导的含有Sp1和野生型PR-B的复合物,而非S345A或mPro PR-B,被募集到内源性p21启动子内的Sp1位点。在含有野生型PR-B并经EGFR、c-Src或MAPK激酶抑制剂处理的T47D细胞中,或在稳定表达mPro或突变型DNA结合域PR-B的T47D细胞中,孕激素诱导的S期进入减弱。总之,孕激素快速激活的PR信号传导导致PR的Ser345磷酸化并与Sp1结合。这些事件对于孕激素刺激的Sp1靶基因调控和乳腺癌细胞增殖至关重要。我们的数据表明,通过利用PR信号通路中的多个节点,包括PR-B、EGFR、c-Src、MAPK或Sp1,进行靶向PR的乳腺癌治疗具有治疗潜力。